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MicroRNA-142 Reduces Monoamine Oxidase A
Expression and Activity in Neuronal Cells by
Downregulating SIRT1
Amrita Datta Chaudhuri, Sowmya V. Yelamanchili, Howard S. Fox*
Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, Nebraska, United States of America
Abstract
Aberrant expression of microRNAs (miRs) has been implicated in the pathogenesis of several neurodegenerative disorders.
In HIV-associated neurocognitive disorders (HAND), miR-142 was found to be upregulated in neurons and myeloid cells in
the brain. We investigated the downstream effects of chronic miR-142 upregulation in neuronal cells by comparing gene
expression in stable clones of the human neuroblastoma cell line BE(2)M17 expressing miR-142 to controls. Microarray
analysis revealed that miR-142 expression led to a reduction in monoamine oxidase (MAO) A mRNA, which was validated by
qRT-PCR. In addition to the mRNA, the MAOA protein level and enzyme activity were also reduced. Examination of primary
human neurons revealed that miR-142 expression indeed resulted in a downregulation of MAOA protein level. Although
MAOA is not a direct target of miR-142, SIRT1, a key transcriptional upregulator of MAOA is, thus miR-142 downregulation of
MAOA expression is indirect. MiR-142 induced decrease in MAOA expression and activity may contribute to the changes in
dopaminergic neurotransmission reported in HAND.
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Introduction
MicroRNAs (miRs) fine-tune gene expression at the post-
transcriptional level thereby regulating various cellular processes.
They bind to the 39 untranslated region (UTR) of target mRNAs
and recruit the RNA-induced silencing complex (RISC) to
downregulate expression of the target. MiRs have emerged as
important regulators of neuronal function, their altered expression
contributing to neuronal dysfunction in diseases of the central
nervous system (CNS) [1,2], including HIV-associated neurocog-
nitive disorders (HAND) [3–8]. Since HIV does not infect
neurons, the neuronal pathology of HAND is secondary to CNS
inflammation [9]. In recent years, implementation of combined
antiretroviral therapy (cART) has resulted in lower plasma and
CSF viral load and higher CD4+ cell counts in HIV infected
patients [10]. Therefore, HIV-infected patients now live longer.
However, this chronicity may further pre-dispose them to age-
related cognitive impairment and the prevalence of HAND has
increased despite implementation of cART [11]. One pathological
manifestation of HIV infection that can lead to a severe form of
HAND is HIV encephalitis (HIVE), where inflammatory cytokines
and chemokines as well as HIV proteins cause changes in neuronal
gene expression, leading to neuronal dysfunction and death [9,12].
Elucidation of novel molecular mechanisms that contribute to the
neuronal dysfunction in HIVE is necessary, as it will provide
insights into pathogenesis of not only HAND, but also other
degenerative diseases associated with CNS inflammation.
Alteration of the brain miR expression profile in HIVE and its
non-human primate model (simian immunodeficiency virus
encephalitis, SIVE) has been reported in previous studies [3–7].
Among the miRs that were found to be differentially expressed in
the disease condition compared to uninfected control samples,
miR-142 was upregulated both in the frontal cortex white matter
in humans [7], as well as in the caudate nucleus and hippocampus
in monkeys and caudate nucleus in humans [6]. In a previous
study we showed that in the brain, miR-142 is upregulated within
neurons and macrophage/microglia nodules in SIVE [8]. We also
identified the NAD-dependent deacetylase Sirtuin1 (SIRT1) as a
direct target for miR-142-5p, one of the two functional mature
forms of miR-142 [8]. MiR-142 has been extensively studied in the
hematopoietic cell lineage, where it regulates differentiation of T
lymphocytes and myeloid cells [13–16]. In addition to SIVE, miR-
142 expression in neurons has been reported following nerve crush
injury [17] and cocaine treatment [18]. However, very little is
known about downstream effects of chronic miR-142 upregulation
in neuronal cells. In this context, in vitro miR-142 has been shown
to target the transcripts of key neuronal genes encoding the D1
dopamine receptor (DRD1) [19] and the Clock-partner aryl
hydrocarbon receptor nuclear translocator-like (ARNTL or
BMAL1) [20-22], both of which play important roles in neuronal
function. These studies, like most with miRs, were conducted after
transient overexpression of miR-142.
The goal of the present study was to identify neuronal genes
affected by chronic miR-142 upregulation and that may contrib-
ute to the neuronal pathology in HAND. We report that chronic
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overexpression of miR-142 in a neuronal cell line leads to
downregulation of expression and activity of the neurotransmitter-
metabolizing enzyme monoamine oxidase (MAO) type A.
Decrease in MAOA protein level was also confirmed in primary
human neurons that were transduced with miR-142. The MAOA
39UTR does not have any binding sites for either miR-142-3p or -
5p. Previously we identified SIRT1 as a direct target of miR-142;
SIRT1 is downregulated in cell lines and neurons overexpressing
miR-142 [8] and is known to induce MAOA expression [23].
Therefore, we postulate that miR-142 decreases MAOA expres-
sion by reducing SIRT1 protein level. Accordingly, overexpression
of SIRT1 restored MAOA protein expression levels. Downregu-
lation of SIRT1 by miR-142 therefore leads to the reduction in
MAOA expression and activity, and may contribute to the
changes in catecholaminergic neurotransmission in HAND.
Materials and Methods
Ethics Statement
For primary human neuron culture, fetal brain tissue was
obtained in full compliance with the ethical guidelines of the NIH
from the Birth Defects Laboratory, University of Washington,
Seattle, WA, USA, where written informed consent from the next
of kin was obtained for use of this sample in research under
Institutional Review Board approval (#96-1826-A07). All research
work was performed under Institutional Review Board approval
(#009-00-FB) from the University of Nebraska Medical Center,
Omaha, NE.
Cell lines and primary neuron culture
BE(2)M17 neuroblastoma cells (obtained from the American
Type Culture Collection (ATCC), Manassas, VA, cat. #CRL-
2267), were cultured in Dulbecco’s Modified Eagle Medium with
F12 and Glutamax (Gibco, NY, USA) containing 10% fetal bovine
serum, 500 U/mL penicillin and 500 mg/mL streptomycin
(Gibco, NY, USA). All cell lines were maintained at 37uC in
95% air and 5% CO2.
For primary human neuron culture, fetal brain tissue was
incubated with 0.25% trypsin for 30 minutes, neutralized with
10% fetal bovine serum and further dissociated by trituration. The
resulting single-cell suspension was cultured on poly-D-lysine
coated plates in Neurobasal medium supplemented with 0.5 mM
l-glutamine, 500 U/mL penicillin and 500 mg/mL streptomycin
and B27 supplement (Gibco, NY, USA). Neurons were cultured in
vitro for 11 days before any experiment. To confirm purity of
primary neuron culture, they were stained for MAP2 (1:1500)
(Sternberger Monoclonals Inc, MD, USA).
Preparation of stable BE(2)M17 clones expressing miR-
142 and miR-null
BE(2)M17 neuroblastoma cells were transfected either with
pEP-miR-142 or a pEP-miR-null plasmid (Cell Biolabs, CA, USA)
using Neuromag transfection reagent (Oz Biosciences, France)
according to manufacturer’s protocol. Seventy-two hours after
transfection, the medium was changed to selection medium
containing 4 mg/mL puromycin. Three independent miR-142
and miR-null clones were picked and miR-142 expression was
confirmed by qRT-PCR using TaqMan microRNA assay
(Applied Biosystems, CA, USA) for miR-142-3p and -5p, and
U6 snRNA as endogenous control. Relative expression was
calculated using efficiency corrected Ct method as described
previously [24].
Microarray analysis and mRNA qRT-PCR for BE(2)M17
clones
Gene array was performed using GeneChip Human Exon 1.0
ST Array (Affymetrix, CA, USA) by UNMC microarray core
facility and the results were analyzed using Partek Genomics Suite
(Partek Incorporated, MO, USA). The microarray data have been
deposited in NCBI GEO, accession #GSE50133. Genes down-
regulated in the miR-142 clones with a p-value ,0.001 were
validated by qRT-PCR, which was performed using TaqMan 96-
well array (Applied Biosystems, CA, USA) with GAPDH, HPRT1
and GUSB as endogenous controls. Relative expression was
calculated using efficiency corrected Ct method as described
previously [24].
Western Blotting
Whole cell lysates were prepared using RIPA buffer (50 mM
Tris-HCl pH 8, 150 mM NaCl, 1% NP40, 0.5% sodium
deoxycholate, 0.1% SDS) and protein quantification was carried
out using Pierce BCA protein assay (Thermo Scientific, IL, USA).
Five to 15 mg of protein was loaded in each lane of NuPAGE 4–
12% Bis-Tris gels (Invitrogen, CA, USA). Separated proteins were
transferred onto nitrocellulose membranes using iBlot (Invitrogen,
CA, USA). The membranes were blocked in SuperBlock (TBS)
blocking buffer (Thermo Scientific, IL, USA) and then incubated
overnight at 4uC with primary antibody. The following primary
antibodies were used: rabbit polyclonal Sirtuin 1 (SIRT1) (1:200),
rabbit polyclonal Monoamine Oxidase A (MAOA) (1:400) (Santa
Cruz Biotechnology, CA, USA), rabbit polyclonal actin (1:5000)
(Sigma Aldrich, MO, USA). This was followed by incubation with
secondary antibody; horseradish peroxidase conjugated anti-rabbit
IgG (1:20,000) (Thermo Scientific, IL, USA), for 1 hour at room
temperature. Blots were developed using SuperSignal West Pico
Chemiluminescent Substrate (Thermo Scientific, IL, USA),
imaged and quantified using Carestream MI software.
Monoamine oxidase (MAO) enzyme activity assay
Mitochondria were isolated from miR-142 and miR-null
expressing BE(2)M17 clones using mitochondria isolation kit for
cultured cells (MitoSciences, OR, USA). Total MAO, MAOA and
MAOB enzyme activity was quantified using Amplex Red
Table 1. Summary of microarray and qRT-PCR analyses
comparing differences in gene expression between stable
BE(2)M17 clones expressing miR-142 and miR-null.
Gene Symbol Gene Array qRT-PCR
Fold Change p value Fold Change p value
CYP2S1 23.79 4.2E-06 N.D. N.D.
DEPDC6 24.23 6.3E-05 21.27 0.318
ADAMTS2 22.85 6.4E-05 211.79 0.110
AKAP12 22.33 1.6E-04 23.07 0.007
BAMBI 23.21 3.7E-04 22.97 0.155
GNG8 23.09 4.1E-04 21.19 0.441
MAOA 22.81 8.3E-04 25.74 0.013
PLD5 22.66 9.7E-04 23.07 0.146
Genes that were found to be down-regulated in the miR-142 clones with a p-
value ,0.001 in the microarray analysis are shown here. Only MAOA and
AKAP12 showed significant (p , 0.05) down-regulation in the post-validation
experiment using RT-PCR.
doi:10.1371/journal.pone.0079579.t001
MicroRNA-142 Reduces MAOA Expression and Activity
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Monoamine Oxidase Assay Kit (Invitrogen, CA, USA). The
enzyme activity was normalized to total protein content in each
sample.
Preparation of miR-142 expressing lentivirus and
transduction of primary human neurons
Lentivirus expressing miR-142 was prepared as described
previously [25]. First, the BamH1 restriction site present upstream
of the pre-miR-142 sequence in the pEP-miR-142 expression




The PCR product was run on a 1% agarose gel and was
extracted from the band corresponding to the length of pre-miR-
142 fragment (approximately 300 base pairs) using QIAquick gel
extraction kit (Qiagen, Valencia, CA). The FUGW vector was
digested with PacI and NheI to generate sticky ends corresponding
to that of the pre-miR-142 fragment from the mutated pEP-miR-
142 expression vector. The pre-miR-142 fragment was then
ligated to the FUGW vector using T4 DNA ligase (Invitrogen,
Carlsbad, CA). The ligated DNA was transformed into Stbl2 cells.
Several colonies were picked and screened for the pre-miR-142
sequence using double digestion with PacI and NheI followed by
separation and visualization on 1% agarose gel. DNA from
colonies that were positive for pre-miR-142 sequence was sent to
the UNMC DNA sequencing core facility to confirm the presence
of pre-miR-142 sequence.
HEK293T cells were transfected with miR-142-FUGW, D8.9
and vesicular stomatitis virus G protein using XtremeGene HP
transfection reagent (Roche Applied Science, IN, USA) according
to manufacturer’s protocol. Cell supernatant containing virions
was collect 48 hour and 72 hour after transfection, and concen-
trated by ultracentrifugation at 25,000 rpm for 90 minutes.
FUGW without precursor miR-142 insert was used as control.
Lentivirus titer was determined using HIV p24 ELISA assay
(Express Biotech International, MD, USA).
Primary human neurons were grown in vitro for 11 days and
transduced with miR-142 or control lentivirus at a concentration
of 56106 lentiviral particles/mL. Successful transduction was
confirmed by visualizing GFP expression. Six days after transduc-
tion cells were collected for Western blotting and qRT-PCR.
Transient transfection of BE(2)M17 clones with SIRT1
Flag-tagged SIRT1 plasmid was obtained from Addgene
(Addgene, Cambridge, MA, plasmid 1791) [26]. Transfections
Figure 1. miR-142 downregulates MAOA protein expression
and enzyme activity in BE(2)M17 cells. (A) Representative Western
blot for MAOA in stable BE(2)M17 clones expressing miR-142 and in
control miR-null clones. (B) Quantification of three independent
Western blots showing that MAOA protein level is lower (-3.5 fold) in
stable BE(2)M17 clones expressing miR-142 compared to miR-null
clones. Blots were normalized to b-actin and unpaired t-test was
performed. *** represent p,0.001, error bars are standard error of
mean. (C) Total MAO as well as MAOA and MAOB specific activity was
measured in the miR-142 and miR-null BE(2)M17 clones. Both total MAO
and MOA specific activity was approximately 40% lower in miR-142
clones compared to miR-null clones. There was no difference in MAOB
specific activity. Y-axis represents fold change of enzyme activity, error
bars represent standard error of mean, n = 3.
doi:10.1371/journal.pone.0079579.g001
Figure 2. miR-142 downregulates MAOA protein expression in
human neurons. Human neurons grown in vitro for 11 days were
transduced with either miR-142 or GFP lentivirus. On day 6 after
transduction, cells were harvested and Western blot analysis was
performed for MAOA. Representative Western blots from three human
neuron donors indicating a decrease in MAOA protein level after miR-
142 transduction compared to control GFP transduction are shown.
Quantification of Western blots from 5 human neuron donors revealed
a significant decrease in MAOA level after miR-142 transduction (fold
change -1.9, p,.05). Blots were normalized to b-actin and paired t-test
was performed.
doi:10.1371/journal.pone.0079579.g002
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were preformed with Neuromag transfection reagent according to
the manufacturer’s protocol. Cells were harvested 48 hours after
transfection.
Statistical Analysis
Statistical analysis was performed using Prism software
(GraphPad, CA, USA) unless otherwise stated. Paired or unpaired
Student’s t-test, or one-way ANOVA followed by Bonferroni’s
multiple correction test was performed as applicable.
Results
Stable overexpression of miR-142 in BE(2)M17 cells
reduces MAOA mRNA expression level
To identify miR-142-regulated genes relevant to neuronal
pathophysiology, we created stable clones of BE(2)M17 neuro-
blastoma cells expressing miR-142 or the control plasmid, denoted
miR-null. The BE(2)M17 cell line was chosen because it does not
express any endogenous miR-142. Overexpression of miR-142-3p
and -5p in the stable BE(2)M17 clones was confirmed by
performing qRT-PCR for the respective mature miRs. RNA
was extracted from three independent miR-142 clones and three
miR-null clones, and microarray analysis was performed to
determine the differences in gene expression. Given the large
number of genes examined, we used p-value cut-off of p,0.001
and a fold change .2.5 to identify the top candidate genes. The
expression of eight genes was altered between the miR-142- and
miR-null-expressing clones using these criteria. qRT-PCR re-
vealed that all except one, that was not detectable, were decreased
in the miR-142 expressing cells. However, the decrease in
expression of only MAOA and AKAP12 reached significance
(Table 1). As MAOA is an important neurotransmitter-metabo-
lizing enzyme, the decrease in expression of which may contribute
to neuronal dysfunction, we chose to focus on MAOA for further
studies.
miR-142-overexpressing clones have lower MAOA
protein levels and enzyme activity
Western blot analysis was performed with whole cell lysates
from three stable BE(2)M17 clones expressing miR-142 (clones 6B,
6C and 6G) and three miR-null clones (1A, 2A, 2B). In addition to
reduction in MAOA mRNA level, MAOA protein level was 3.5
fold lower in the miR-142-expressing clones compared to the miR-
null clones (Figure 1 A, B).
Next we investigated whether the decrease in MAOA expres-
sion in neuronal cells translates to a deficit in its activity. There are
two enzymes with MAO activity in cells, MAOA and MAOB,
both of which are localized to the outer membrane of the
mitochondria. We isolated mitochondria from miR-142 and miR-
null clones to enrich for the MAOs, and tested each for MAO
enzyme activity, using the specific inhibitors, clorgyline to inhibit
MAOA activity and pargyline to inhibit MAOB activity. Similar
to the protein levels, both total MAO and MAOA specific activity
was found to be about 40% lower in miR-142 clones compared to
miR-null clones. There was no difference in MAOB activity
(Figure 1C).
Overexpression of miR-142 in primary human neurons
leads to decrease in MAOA protein levels
To confirm that these observed effects also occur in primary
neurons, human neurons were cultured in vitro for 11 days. They
were then transduced with either a miR-142 expressing lentivirus
or a control GFP lentivirus. Cells were harvested 6 days after
transfection. Expression levels of miR-142-3p and -5p were
confirmed by performing qRT-PCR. Western blot for MAOA
with whole cell lysates from five independent primary human
neuron donors revealed that MAOA protein level was 1.9 fold
lower (p,0.05, n = 5) in neurons transduced with miR-142
compared to those transduced with the control GFP lentivirus
(Figure 2).
Overexpression of SIRT1 restores MAOA protein levels in
miR-142-overexpressing BE(2)M17 clones
Bioinformatic analysis indicated that the MAOA 39-UTR does
not have predicted binding sites for miR-142, and luciferase
reporter assays examining revealed no effect of miR-142 on the
MAOA 39-UTR (data not shown). Since miR-142 expression leads
to decreased levels of SIRT1 [8], and SIRT1 can act on the
Figure 3. Overexpression of SIRT1 in BE(2)M17 clones leads to
increase in MAOA protein levels. (A) Representative Western blot
for SIRT1 and MAOA in BE(2)M17 clones 1A (miR-null) and 6B (miR-142).
As predicted, clone 6B has lower levels of SIRT1 compared to clone 1A.
Transfection of SIRT1 results in overexpression of the same, as well as
increase in MAOA protein levels in both the clones. (B) Quantification of
MAOA expression by Western blot analysis after three independent
transfection experiments. MAOA protein level was increased by 1.7-fold
in clone 1A and 1.8-fold in clone 6B after transfection of SIRT1. Blots
were normalized to b-actin and one-way ANOVA was performed
followed by Bonferroni’s multiple correction test. ** represent p,0.01,
* represents p,0.05, error bars are standard error of mean, NT =
non-transfected.
doi:10.1371/journal.pone.0079579.g003
MicroRNA-142 Reduces MAOA Expression and Activity
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MAOA promoter to upregulate its expression [23], we hypoth-
esized that introduction of additional SIRT1 would increase the
level of MAOA. We therefore transfected one of the miR-142
(clone 6B) and one of the miR-null clones (clone 1A) with a SIRT1
expression plasmid (lacking the 39-UTR with the miR-142
recognition site). The cells were harvested 48 hours after
transfection. While as expected the Western blot analysis showed
that SIRT1 protein level was lower (fold change = -2.3, p,0.05,
n = 3) in the miR-142 expressing clone compared to the miR-null
clone, in both clones increased expression of the SIRT1 protein
level following the transfections led to an increase in MAOA
protein level (miR-null clone 1A, fold change = 1.7, p,0.01,
n = 3; miR-142 clone 6B, fold change = 1.8, p,0.05, n = 3)
(Figure 3A, B).
Discussion
In this study we have elucidated a novel molecular mechanism
of miR-mediated regulation of MAOA expression neuronal cells.
Chronic overexpression of miR-142 led to decrease in MAOA
mRNA and protein levels, as well as a reduction in the enzyme
activity. This regulation of MAOA expression and activity by
miR-142 is mediated indirectly through repression of the direct
miR-142-5p target, SIRT1, that otherwise induces MAOA
expression. Decrease in MAOA expression and activity may
contribute to the reported changes in neurotransmitter metabolism
in HAND, ultimately leading to neuronal dysfunction (Figure 4).
MiR-142 has two functionally active mature strands, miR-142-
3p and -5p. In HIVE/SIVE both strands of miR-142 are
upregulated [6,7]. MiR-142 is known to be expressed in the cells
of the hematopoietic lineage [13]. However, in brain sections from
rhesus macaques with SIVE, co-localization studies with cell type
markers showed that in addition to myeloid cells, miR-142 is
expressed both in neurons as well [8]. Upregulation of neuronal
miR-142 expression was also reported following peripheral nerve
crush [17] and cocaine treatment [18]. In order to investigate the
downstream effects of such increase in neuronal miR-142
expression we compared gene expression of stable BE(2)M17
clones expressing miR-142 to clones that were transduced with
miR-null. Among the significantly differentially expressed genes,
we chose to focus on MAOA for further studies.
MAOs are neurotransmitter-metabolizing enzymes located on
the outer mitochondrial membrane. There are two isoforms of
MAO, MAOA and MAOB, having about 70% sequence
homology but distinct substrate specificities. MAOA preferentially
deaminates serotonin, melatonin, epinephrine and norepineph-
rine, while MAOB has higher affinity for dietary amines like
phenethylamine. Both isoforms have similar affinity for dopamine
[27]. Congruent with its prime role in neurotransmitter catabo-
lism, pharmacological and genetic evidence has linked MAOA
with mood and emotion [28-32]. We found that miR-142 over-
expression in neuronal cell lines and neurons results in lower
MAOA mRNA and protein levels, as well as enzyme activity.
These cells will therefore have impaired monoaminergic neuro-
transmitter catabolism.
Dysfunction of the dopaminergic systems has been reported in
HAND [33–35]. Dopaminergic neurotransmission is reduced in
advanced stages of the disease as evidenced by reduction in
dopamine levels in post-mortem brain and CSF samples. This may
be a result of progressive loss of dopaminergic neurons in the
brain. However, in early stages of the disease, an increase in
dopaminergic tone has been observed. Treatment naı̈ve asymp-
tomatic HIV patients have higher levels of dopamine in the CSF
due to decrease in dopamine turnover, as evidenced by lower CSF
levels of the dopamine metabolite, homovallinic acid [33]. This
suggests a possible decrease in activity of dopamine-catabolizing
enzymes, such as MAO and Catechol-O-Methyl Transferase,
early in the disease. Upregulation of miR-142 may contribute to
such changes in dopaminergic neurotransmission in the disease by
lowering MAOA expression and activity.
Although miR-142 expressing cells had lower MAOA expres-
sion and activity, miR-142 cannot target MAOA directly as there
are no miR-142 recognition elements in the MAOA 39UTR.
Therefore regulation of MAOA by miR-142 must be mediated by
a direct miR-142 target. In this context, the NAD-dependent
deacetylase SIRT1, was reported to regulate transcription of
MAOA [23]. SIRT1 deacetylates and activates the transcription
factor NHLH2, inducing MAOA expression [23]. SIRT1 is also a
validated target for miR-142-5p [8]. Cells that express high levels
of miR-142 in SIVE have lower SIRT1 protein levels [8].
Decrease in SIRT1 levels due to upregulation of miR-142 could
therefore explain this decrease in MAOA expression and activity.
Figure 4. Schematic representation of downstream effects of miR-142 upregulation in neurons. Normally, uninfected neurons have
minimal miR-142 expression. Most of the SIRT1 mRNA is therefore available for translation, maintaining the SIRT1 protein pool. SIRT1 deacetylates a
lysine residue in the transcription factor NHLH2 and activates it. NHLH2 in turn increases MAOA transcription. In HIVE/SIVE, miR-142 expression is
upregulated in neurons. One of the two mature strands of this miR, miR-142-5p, binds to the 39UTR of SIRT1 mRNA and prevents its translation. This
leads to reduction of SIRT1 protein level. Therefore SIRT1 is no longer available for induction if MAOA expression, finally resulting in decrease in
MAOA expression and activity.
doi:10.1371/journal.pone.0079579.g004
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Indeed, we found that overexpression of SIRT1 in the BE(2)M17
clones could increase MAOA protein level.
In addition to neurons, upregulation of miR-142 was also
observed in myeloid cells in the SIVE brain [8]. Recent studies
have demonstrated that myeloid cells express components of the
dopaminergic system including dopamine receptors, dopamine
transporters and the dopamine synthesizing enzyme tyrosine
hydroxylase [36–38]. MAOA is also expressed in monocytes/
macrophages where it is strongly induced by the Th2 cytokines IL-
4 and IL-13; although its function in these cell types is not clear it
is speculated that it serves an immunomodulatory role [39].
Further investigation is therefore required to elucidate the
functional effect of upregulation of miR-142 and downregulation
of MAOA in microglia/macrophages in SIVE.
In conclusion, we found that chronic increase in neuronal miR-
142 expression leads to decrease in MAOA expression and
activity. This effect of miR-142 on MAOA expression level is
mediated by downregulation of the direct miR-142-5p target
SIRT1. Upregulation of miR-142 may therefore contribute to
changes in dopaminergic neurotransmission reported in HAND.
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